Toxikon Corp. is moving forward with a plan to expand a portion of its Bedford, MA campus for its Efficacy and Surgical Research Services. The expansion is expected to be complete in August and will include accommodations for more animal model development, trainings, demonstrations, and remote visualization of procedures and surgeries.

According to the company, the modifications will provide Toxikon’s research and product development clientele with resources and scientific capabilities typically found only in academic settings.

“For more than 30 years, Toxikon has been dedicated to the development of therapies and medicals devices that ultimately save lives, treat illness and prevent injuries,” said Dr. Laxman S. Desai, Toxikon’s president and chief executive officer. “Our new and expanded capability for efficacy and surgical research reinforces our commitment to the development of tomorrow’s life saving medical devices and drugs.”

The facility will have space for large and small animal models. Dr. Curtis Schondelmeyer, Toxikon’s director of Preclinical Veterinary Services, said, “Along with two vivaria, there are surgical and procedure spaces outfitted with the latest in surgical equipment, monitoring, and imaging equipment.”

According to Dr. Schondelmeyer, the fully staffed ESRS team can provide full hematological assessments, biochemistry, analytical, and pathology, and allows Toxikon to meet the efficacy and surgical service demands of its growing client base. “Our facilities are also equipped to handle multiple surgical stations to accommodate physician trainings and demonstrations,” he remarked. “We can accommodate large groups and even provide remote visualization of procedures and surgeries within our facilities and around the world.”